Infections by Organism: Fungi
Aspergillus
Blastomycosis
Coccidioidomycosis
Cryptococcal Disease .jpg?n=1977 "New")
Candidiasis
Histoplasmosis
Sporotrichosis
Aspergillus
"Treatment of Aspergillosis"
Clinical Infectious Diseases 2008; 46:327–360
Aspergillus species have emerged as an important cause of life-threatening infections in immunocompromised patients. This expanding population is composed of patients with prolonged neutropenia, advanced HIV infection, and inherited immunodeficiency and patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) and/or lung transplantation. This document constitutes the guidelines of the Infectious Diseases Society of America for treatment of aspergillosis and replaces the practice guidelines for Aspergillus published in 2000. more »
.JPG?n=4178 "asperd") |
Order the pocketcard! |
Aspergillus 2000 Guideline (PDF)
Aspergillus Guideline-Spanish Version
Blastomycosis
"Clinical Practice Guidelines for the Management of Blastomycosis"
Clinical Infectious Diseases 2008;46:1801–1812
Blastomycosis refers to disease caused by the dimorphic fungus Blastomyces dermatitidis. This infection occurs most often in persons living in midwestern, southeastern, and south central United States and the Canadian provinces that border the Great Lakes and the St. Lawrence Seaway. Recent reports have shown an increase in the incidence of blastomycosis in some of these regions. more »
Blastomycosis 2000 Guideline (PDF)
Coccidioidomycosis
"Practice Guidelines for the Treatment of Coccidioidomycosis"
Clinical Infectious Diseases 2005;41:1217–1223
Management of coccidioidomycosis first involves recognizing that a coccidioidal infection exists, defining the extent of infection, and identifying host factors that predispose to disease severity. After these assessments, patients with localized acute pulmonary infections and no risk factors for complications often require only periodic reassessment to demonstrate resolution of their self-limited process. On the other hand, patients with extensive spread of infection or who are at high risk of complications because of immunosuppression or other preexisting factors require a variety of treatment strategies that may include antifungal drug therapy, surgical debridement, or a combination of both. more »
Coccidioidomycosis 2000 Guideline (PDF)
Cryptococcal Disease
"Practice Guidelines for the Management of Cryptococcal Disease"
Clinical Infectious Diseases 2010; 50: 291-322
Cryptococcosis is a global invasive mycosis associated with significant morbidity and mortality. These guidelines for its management have been built on the previous Infectious Diseases Society of America guidelines from 2000 and include new sections. There is a discussion of the management of cryptococcal meningoencephalitis in 3 risk groups: (1) human immunodeficiency virus (HIV)–infected individuals, (2) organ transplant recipients, and (3) non–HIV‐infected and nontransplant hosts. There are specific recommendations for other unique risk populations, such as children, pregnant women, persons in resource‐limited environments, and those with Cryptococcus gattii infection. more »
Cryptococcal Disease Guideline 2000 (PDF)
Candidiasis
"Guidelines for Treatment of Candidiasis"
Clinical Infectious Diseases 2009; 48:503–535
Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by health care providers who care for patients who either have or are at risk of these infections. more »
 |
Order the pocketcard! |
Candidiasis Guideline Spanish Version
Candidiasis 2000 Guideline (PDF)
Histoplasmosis
"Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of America"
Clinical Infectious Diseases 2007; 45:807–25
These updated guidelines replace the previous treatment guidelines published in 2000. The guidelines are intended for use by health care providers who care for patients who either have these infections or may be at risk for them. Since 2000, several new antifungal agents have become available, and clinical trials and case series have increased our understanding of the management of histoplasmosis. Advances in immunosuppressive treatment for inflammatory disorders have created new questions about the approach to prevention and treatment of histoplasmosis. more »
Histoplasmosis 2000 Guideline (PDF)
Sporotrichosis
"Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America"
Clinical Infectious Diseases 2007; 45:1255–65
Guidelines for the management of patients with sporotrichosis were prepared by an Expert Panel of the Infectious Diseases Society of America and replace the guidelines published in 2000... They include evidence-based recommendations for the management of patients with lymphocutaneous, cutaneous, pulmonary, osteoarticular, meningeal, and disseminated sporotrichosis. Recommendations are also provided for the treatment of sporotrichosis in pregnant women and in children. more »
Sporotrichosis 2000 Guideline (PDF)